Tumour-induced osteomalacia (TIO)

Endokrynol Pol. 2022;73(5):903-904. doi: 10.5603/EP.a2022.0033.

Authors

Agnieszka Molendowska¹, Joanna Jakubowska², Diana Jędrzejuk³, Jadwiga Szymczak³

Affiliations

¹ Department and Clinic of Endocrinology, Diabetology, and Isotope Therapy of Wrocław Medical University, Wroclaw, Poland. agapet86@gmail.com.
² Department of Endocrinology, Diabetology, and Isotope Therapy, University Hospital of Wroclaw, Wroclaw, Poland.
³ Department and Clinic of Endocrinology, Diabetology, and Isotope Therapy of Wrocław Medical University, Wroclaw, Poland.

PMID: 36621920
DOI: 10.5603/EP.a2022.0033

Abstract

Not required for Clinical Vignettes.

Keywords: FGF23; TIO; hypophosphataemia; hypophosphataemic osteomalacia.

MeSH terms

Fibroblast Growth Factors
Humans
Hypophosphatemia* / chemically induced
Osteomalacia* / etiology
Paraneoplastic Syndromes* / etiology

Substances

Fibroblast Growth Factors

Supplementary concepts

Oncogenic osteomalacia